Premium
Identification of early candidate urine biomarkers for measure Escitalopram treatment response from major depressive disorder
Author(s) -
Huan Yuhang,
Wei Jing,
Zhou Jingjing,
Liu Min,
Yang Jian,
Gao Youhe
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2020.34.s1.02855
Subject(s) - escitalopram , major depressive disorder , respondent , urine , psychology , medicine , clinical psychology , antidepressant , political science , hippocampus , law , mood
Major depressive disorder (MDD) is a common mental disorder that can cause substantial impairments in quality of life. Clinical treatment is usually built on trial and error method, which lasts about 12 weeks to evaluate whether the treatment is efficient or not, leading some inefficient treatment measures. We therefore identify early candidate urine biomarkers to predict efficient treatment response in MDD patients. In this study, urine samples were collected from 10 respondent and 10 non‐respondent to escitalopram MDD patients with 0‐, 2‐, and 12‐week treatment. Differential urinary proteins were then analyzed by liquid chromatography coupled with tandem mass spectrometry (LC‐MS/MS). On week 2, there were 14 differential proteins identified in response group when compared with week 0 and these proteins can’t be enriched by random allocation analysis, 10 among which have been associated with the mechanisms of MDD. While in non‐response group, there were 35 differential proteins identified on week 2, and 18 among which have been associated with the mechanisms of MDD. In addition, differential urinary proteins on week 2 between respondent and non‐response group can be distinguished clearly by using Orthogonal Partial Least Squares Discrimination Analysis (OPLS‐DA). Our small pilot results indicated that the urine proteome can reflect early changes between respondent and non‐respondent group to escitalopram therapy since on week 2, which will provide potential early candidate urine biomarkers to predict efficient treatment measures in MDD patients. Support or Funding Information This research was supported by the National Key Research and Development Program of China (2018YFC0910202, 2016 YFC 1306300), the Key Basic Research Program of the Ministry of Science and Technology of China (2013FY114100), the Beijing Natural Science Foundation (7173264, 7172076), the Beijing cooperative construction project (110651103), the Beijing Normal University (11100704), the Peking Union Medical College Hospital (2016–2.27), and Beijing Biobank of Clinical Resources‐‐Mental Disorders, BBCR‐MD.